NO955189L - En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet - Google Patents

En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet

Info

Publication number
NO955189L
NO955189L NO955189A NO955189A NO955189L NO 955189 L NO955189 L NO 955189L NO 955189 A NO955189 A NO 955189A NO 955189 A NO955189 A NO 955189A NO 955189 L NO955189 L NO 955189L
Authority
NO
Norway
Prior art keywords
growth factor
keratinocyte growth
disclosed
kgf
abbreviated
Prior art date
Application number
NO955189A
Other languages
English (en)
Norwegian (no)
Other versions
NO955189D0 (no
Inventor
Denis Gospodarowicz
Frank Masiarz
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO955189D0 publication Critical patent/NO955189D0/no
Publication of NO955189L publication Critical patent/NO955189L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
NO955189A 1993-06-29 1995-12-20 En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet NO955189L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
PCT/US1994/004694 WO1995001434A1 (en) 1993-06-29 1994-04-28 A truncated keratinocyte growth factor (kgf) having increased biological activity

Publications (2)

Publication Number Publication Date
NO955189D0 NO955189D0 (no) 1995-12-20
NO955189L true NO955189L (no) 1995-12-20

Family

ID=22198501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO955189A NO955189L (no) 1993-06-29 1995-12-20 En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet

Country Status (25)

Country Link
US (7) US5677278A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1493812A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (4) JP3570516B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR960703433A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1129955A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE278777T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU681405B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG100236A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9407035A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2166278A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ343795A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE122006000005I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0706563T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2227527T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI956203A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR06C0004I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT73453A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91215I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300217I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO955189L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ266622A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL312257A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT706563E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK153295A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995001434A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153816T3 (es) 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
US5965530A (en) * 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
PT706563E (pt) 1993-06-29 2005-01-31 Chiron Corp Factor de crescimento de queratinocitos (kgf) truncado, com actividade biologica aumentada
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
IL147575A (en) * 1994-10-13 2004-05-12 Amgen Inc Method for purifying keratinocyte growth factors
JP4216329B2 (ja) * 1994-10-13 2009-01-28 アムジエン・インコーポレーテツド Ｋｇｆを用いた糖尿病の治療法
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
DK1486565T3 (da) 1995-10-11 2008-03-10 Novartis Vaccines & Diagnostic Kombination af PDGF, KGF, IGF og IGFBP til sårheling
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
AU727678C (en) * 1996-10-15 2005-05-12 Biovitrum Ab (Publ) Keratinocyte growth factor-2 products
EP1473366A1 (en) * 1996-10-15 2004-11-03 Amgen Inc. Keratinocyte growth factor-2 products
EP1003770A4 (en) * 1997-06-19 2002-10-30 Inst Genetics Llc SECRETIED POLYPEPTIDES AND THESE ENCODING POLYNUCLEOTIDES
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
AU1905799A (en) 1997-12-22 1999-07-12 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CN1295579A (zh) * 1998-02-13 2001-05-16 人类基因组科学公司 角质细胞生长因子2的治疗应用
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
AU2039501A (en) 1999-10-15 2001-04-23 Rockefeller University, The System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
EP1414866A2 (en) 2000-11-21 2004-05-06 The Texas A & M University System Fgf-affinity chromatography
AU2002309473A1 (en) * 2001-01-08 2002-10-08 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7430476B2 (en) 2001-02-19 2008-09-30 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
PL374269A1 (en) * 2001-08-21 2005-10-03 Chiron Corporation Kgf polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
RS53548B1 (en) * 2004-12-15 2015-02-27 Swedish Orphan Biovitrum Ab (Publ) THERAPEUTIC FORMULATIONS OF KERATINocyte GROWTH FACTORS
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
MX2016005614A (es) 2013-11-01 2016-12-09 Spherium Biomed S L Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
AU2022336409A1 (en) 2021-08-30 2024-02-15 Unichem Laboratories Limited Protein compositions for the treatment of inflammatory diseases
KR102691028B1 (ko) * 2021-11-15 2024-08-05 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153816T3 (es) 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5965530A (en) 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
PT706563E (pt) * 1993-06-29 2005-01-31 Chiron Corp Factor de crescimento de queratinocitos (kgf) truncado, com actividade biologica aumentada
DK0785950T3 (da) 1994-10-13 2003-07-28 Amgen Inc Keratinocyt vækstfaktoranaloger
JP4216329B2 (ja) 1994-10-13 2009-01-28 アムジエン・インコーポレーテツド Ｋｇｆを用いた糖尿病の治療法

Also Published As

Publication number Publication date
DE122006000005I1 (de) 2006-08-10
DE122006000005I2 (de) 2006-11-23
BR9407035A (pt) 1996-03-12
AU6820894A (en) 1995-01-24
BG100236A (en) 1996-07-31
ES2227527T3 (es) 2005-04-01
DK0706563T3 (da) 2005-01-31
NZ266622A (en) 1997-10-24
HUT73453A (en) 1996-08-28
CZ343795A3 (en) 1996-07-17
JP2006075173A (ja) 2006-03-23
NL300217I2 (nl) 2006-05-01
EP0706563A1 (en) 1996-04-17
NO955189D0 (no) 1995-12-20
DE69434053T2 (de) 2006-02-23
JPH09500267A (ja) 1997-01-14
PT706563E (pt) 2005-01-31
LU91215I2 (en) 2006-03-27
HU9503857D0 (en) 1996-02-28
SK153295A3 (en) 1996-11-06
JP2009062396A (ja) 2009-03-26
US6677301B1 (en) 2004-01-13
ATE278777T1 (de) 2004-10-15
EP1493812A3 (en) 2006-02-08
FR06C0004I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2006-03-10
FI956203A7 (fi) 1996-02-07
US5773586A (en) 1998-06-30
FR06C0004I2 (fr) 2006-12-29
EP0706563B1 (en) 2004-10-06
KR960703433A (ko) 1996-08-17
US5843883A (en) 1998-12-01
US5863767A (en) 1999-01-26
US5677278A (en) 1997-10-14
AU681405B2 (en) 1997-08-28
JP4662569B2 (ja) 2011-03-30
PL312257A1 (en) 1996-04-01
DE69434053D1 (de) 2005-01-20
JP2004166709A (ja) 2004-06-17
FI956203A0 (fi) 1995-12-22
CA2166278A1 (en) 1995-01-12
EP1493812A2 (en) 2005-01-05
CN1129955A (zh) 1996-08-28
JP3570516B2 (ja) 2004-09-29
WO1995001434A1 (en) 1995-01-12
US20090093400A1 (en) 2009-04-09
NL300217I1 (nl) 2006-04-03
US6074848A (en) 2000-06-13

Similar Documents

Publication Publication Date Title
NO955189L (no) En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet
CA1223198A (en) Repair of tissue in animals
Thomas et al. Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity
US5461034A (en) Osteogenic growth polypeptides identified from regenerating bone marrow
BRPI0416683A (pt) muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
JPH02504279A (ja) インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド
IL141494A0 (en) Stable hypoxia inducible factor-1 alpha and method of use
MY102806A (en) Human interleukin-3 and muteins thereof
BR9712348A (pt) molécula de polinucleotídeo isolada, vetor de expressão, célula cultivada em que foi introduzido um vetor de expressão, processo para produzir um polipeptídeo homólogo de fgf, polipeptídeo homólogo de fgf isolado,composição farmacêutica, anticorpo, processos para estimular ex vivo células progenitoras de miócitos, e, paraliberar um agente ou droga seletivamente para o tecido do coração.
CA2223433A1 (en) Ob protein compositions and methods
EP0271211B1 (en) Use of cartilage-inducing factor b (cif-b) for the manufacture of a medicament for inhibiting tumor growth
BR9408006A (pt) Molécula de ácido nucléico isolada e purificada vetor e vetor de express o adaptados para transformaçao de hospedeiro hospedeiro transformado proteina receptora "transferrin" recombinante ou fragmento ou análogo da mesma proteina Tbpl purificada e isolada proteina Tbp2 purificada e isolada peptídeo composiç o imunogênica vetor ativo para fornecimento de proteina receptora "transferrin" vetor de plasmideo linhagem de haemophilus processo para produzir proteina Tbp2 ou Tbpl purificada e isolada
FR2644066B1 (fr) Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
Laato et al. Effect of epidermal growth factor (EGF) on experimental granulation tissue
US5070188A (en) Acylated epidermal growth factor
US5358707A (en) Oxidized variants of GM-CSF
DE69329337D1 (de) Antibiotisches cryptdinpeptid und anwendungsmethoden
EP0526883B1 (en) Chondromodulin-II protein
GB9401689D0 (en) Diagnosis and treatment of endocarditis
EP0241136A3 (en) Human class 1 heparin-binding growth factor
AU632890B2 (en) Fibroblast growth factor for use in the prevention and treatment of viral infections
DE69433221D1 (de) Neues Chondrozytprotein
EP0494664A1 (en) Human bFGF derivatives, their analogs and process for their production
US5883071A (en) Mammalian growth factor
WO1992008473A1 (en) Therapeutic use of fibroblast growth factor